Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1995-06-05
2000-10-17
Brusca, John S.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
435 6, 435 911, 4352402, 435325, 435455, 435375, 536 231, 536 241, 536 245, A61K 4800, C07H 2104, C07H 2102, C12Q 168
Patent
active
061332429
ABSTRACT:
A method and compounds are provided for inhibiting the synthesis of extracellular matrix proteins. Compounds of the invention comprise antisense oligonucleotides specific for nuclear proto-oncogenes. Preferably, antisense compounds of the invention are selected from the group consisting of c-myc and c-myb and are locally administered. The invention finds use in the treatment of a variety of disorders, including sclerotic disorders and restenosis, associated with the inappropriate synthesis of extracellular matrix proteins, particularly collagen.
REFERENCES:
patent: 5245022 (1993-09-01), Weis et al.
patent: 5264423 (1993-11-01), Cohen et al.
patent: 5276019 (1994-01-01), Cohen et al.
patent: 5286717 (1994-02-01), Cohen et al.
patent: 5593974 (1997-01-01), Rosenberg et al.
patent: 5756476 (1998-05-01), Epstein et al.
Gura, T. "Antisense Has Growing Pains", Science vol. 270: 575-577, Oct. 27, 1995.
Wu Pong, S. "Oligonucleotides: Opportunities for Drug Therapy Research", Pharmaceutical Technology. vol. 18: 102-114, Oct. 1994.
Stull, R. et al "Antigene, Ribozyme and Aptamer Nucleic Acid Drugs: Progress and Prospects", Pharmaceutical Research. vol. 12(4): 465-483, 1995.
Bennet, F. "Antisense Research", Science vol. 271:434, Jan. 26, 1996.
Westermann, B. et al "Inhibition of Expression of SV40 virus large T-antigen byAntisense Oligonucleotides", Biomed. Biochim. Acta. vol. 48: 85-93, 1989.
Milligan, J. "Current Concepts in Antisense Drug Design", J. Medicinal Chemistry. vol. 36(14): 1923-1937, Jul. 9, 1993.
Miller, N. et al "Gene Transfer and Antisense Nucleic Acid Techniques", Parisitology Today. vol. 10(3): 92-97, 1994.
Rojanasakul, Y. "Antisense Oligonucleotide Therapeutics: Drug Delivery and Targeting", Advanced Drug Delivery Reviews. vol. 18: 115-131, 1996.
Burgess, T. et al "The Antiproliferative Activity of c-myb and c-myc Antisense Oligonucleotides in Smooth Muscle Cells is Caused by a Nonantisense Mechanism", PNAS vol. 92: 4051-4055, Apr. 1995.
Kulka, M. et al Site Specificity of the Inhibitory Effects of Oligonucleotides Complimentary to the Acceptor Splice Junction of Herpes Simplex Virus Type 1 Immediate Early mRNA 4. PNAS vol. 86: 6868-6872, Sep. 1989.
Wagner, R. "Gene Inhibition Using Antisense Oligonucleotides", Nature vol. 372: 333-335, Nov. 24, 1994.
Watson et al., "Inhibition of cell adhesion to plastic substratum by phosphorothioate oligonucleotide", Experimental Cell Research, 202(2) 391-7 XP000644735 (Oct. 1992).
Wilensky et al., "Methods and devices for local drug delivery in coronary and peripheral arteries", Trends in Cardiovascular Medicine, vol. 3, 163-70, XP000644584 (Sep.-Oct. 1993).
Shi et al., "Regulation of extracellular matrix synthesis by antisense oligomers targeting the c-myc", Circulation 90(4) (Part 2) Abstract 2767, XP000644592 (Oct. 1994).
Shi et al., "C-myc antisense oligomers reduce neointima formation in porcine coronary arteries", Journal of the American College of Cardiology 0 (Spec. Issue), 395A, Abstract 798-5 XP000644587 (Feb. 1994).
Abe et al. "Biochem and Biophysical Research Communications", 198:1:16-24, Jan. 14, 1994.
Agrawal, "Pharmacokinetics, biodistribution, and stability of ligodeoxynucleotide phosphorothioates in mice", Proc. Natl. Acad. Sci. USA vol. 88, pp. 7585-7599, Sep. 1991.
Agrawal, et al., "Antisense Oligonucleotide Based Therapeutic Approach: From Laboratory to Clinical Trials", Antisense Therapy: Efficacy and Delivery of Antisense & Ribozine Oligonucleotide (Feb. 23-25, 1995 London).
Ang et al., "Collagen synthesis by cultured rabbit aortic smooth-muscle cells", Biochem 265:461-469 (1990).
Barinaga M., "Gene Therapy for Clogged Arteries Passes Test in Pigs" Science 265:738, Aug. 5, 1994.
Bauters et al., "Proto-oncogene expression in rabbit aorta after wall injury First marker of the cellular process leading to restenosis after angioplasty" European Heart Journal, 13:556-559 (1992).
Bayever, et al., "Oligonucleotides In The Treatment of Leukemia" Hematological Oncology, vol. 12:9-14, (1994).
Beldekas et al., "Cell Density and Estradiol Modulation of Procollagen Type III in Cultured Calf Smooth Muscle Cells*" The Journal of Biological Chemistry, 257:20:12252-12256, Oct. 25, 1982.
Biro et al., "Inhibitory Effects of Antisense Oligonucleotides targeting c-myc mRNA on Smooth Muscle Cell Proliferation and Migration", Proc. Natl. Acad. Sci. 90:654-658 (1993).
Brown et al., "Expression of the c-myb Proto-oncogene in Bovine Vascular Smooth Muscle Cells*" The Journal of Biological Chemistry, 267:7:4625-4630, Mar. 5, 1992.
Castellot, "Effect of Heparin on Vascular Smooth Muscle Cells . . . ", Journal of Cellular Physiology, 124:21-28 (1985).
Chang and Sonenshein, "Increased Collagen Gene Expression in Vascular Smooth Muscle Cells Cultured in Serum or Isoleucine Deprived Medium", Matrix, vol. 11:242-251 (1991).
Collins et al., "c-myc Antisense Oligonucleotides Inhibit the Colony-Forming Capacity of Colo 320 Colonic Carcinoma Cells", Journal of Clinical Investigation, vol. 89:1523-1527, (1992).
Crooke, "Therapeutic Applications of Oligonucleotides", Annu. Rev. Pharmacol. Toxicol, 32:329-376, (1992).
de Fabritiis, et al., In vitro Purging with BCR-BRL Antisense Oligonucleotide does not Prevent Haematologic Resonstitution After Autologous Bone Marrow Transplantation, Leukemia, 9(4):662-664, (1995).
Dreher et al., "Expression of antisense transcripts encoding an extracellular matrix protein by stably transfected vascular smooth muscle cells" Eur. J. Cell Biol. 54 (1991) pp. 1-9.
Ebbecke et al., "Antiproliferative effects of a c-myc antisense oligonucleotide on human arterial smooth muscle cells" Basic Res Cardiol, 87:585-591 (1992).
Ebbecke et al., "Inhibition of Human Arterial Smooth Muscle Cell Proliferation by a c-myc Antisense Oligonucleotide", Abstract, XIIIth Congress of the European Society of Cardiology Aug. 18-22, 1991, Amsterdam, The Netherlands (No. 677).
Ebecke et al., "In vitro Assessment of Polyactides as Slow Release Drug Carriers", Supplement to Circulation, vol. 84(4), Abstract No. 0285, (1991).
Edelman et al., "Perivascular and Intravenous Administration of Basic Fibroblast Growth Factor: Vascular and Solid Organ Deposition", Proc. Natl. Acad. Sci., vol. 90:1513-1517, (1993).
Edelman et al., "Effect of Controlled Adventitial Heparin Delivery on Smooth Muscle Cell Proliferation Following Endothelial Injury", Proc. Natl. Acad. Sci., vol. 87:3773-3777, (1990).
Edelman et al., "c-myc in Vasculoproliferative Disease", Circulation Research, vol. 76(2): 176-182, (1995).
Epstein et al., "Inhibition of Cell Proliferation using Antisense Oligonucleotides. (Use of c-myc Antisense to Inhibit Cell Proliferation Associated with Restenosis)" NTIS Publication PB93-100576 (Jan. 1, 1993), pp. 1-38.
Fard et al., "Mechanisms of Neointimal Reduction after Transcatheter Delivery of c-myc Antisense Oligomers" Circulation, 90:I-191, abstract No. 1022, Nov. 1994.
Farquharson et al., "Immunolocalization of Collagen Types I and III in the Arterial Wall of the Rat", Histochemical Journal, 21(3):172-178 (1989).
Fernandez-Ortiz et al., "A New Approach for Local Intravascular Drug Delivery", Circulation, vol. 89(4):1518-1522, (1994).
Fox et al., "Fish Oils Inhibit Endothelial Cell Production of Platelet-Derived Growth Factor-Like Protein" Science, 241:453-456 (1988).
Gabbiani et al., "Actin Expression in Smooth Muscle Cells of Rat Aortic Intimal Thickening, Human Atheromatous Plaque, and Cultured Rat Aortic Media" J. Clin Invest., 73:148-152, Jan. 1984.
Gazin et al., "Nucleotide sequence of the human c-myc locus: provocative open reading frame within the first exon" The EMBO Journal, 3:2:383-387, 1984.
Hanke et al., "Prolonged Proliferative Response of Smooth Muscle Cells after Experimental Intravascular Stenting: A Stent Wire Related Phenomenon" Abstract, Supplement to Circulation, 86:4:I-186, Oct. 1992 (0742).
Hiija, et al., Biologic and Therapeutic Significance of MYB Expression in Human Melanona, Proc. Natl. Acad. Sci., vol. 91:4499-4503, (1994).
Holmes et al., "restenosis," from PTCA (Percutaneous Transluminal Coronary Angioplasty), Chapter
Shi Yi
Zalewski Andrew
Brusca John S.
McGarry Sean
Thomas Jefferson Univerisity
LandOfFree
Inhibition of extracellular matrix synthesis by antisense compou does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibition of extracellular matrix synthesis by antisense compou, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of extracellular matrix synthesis by antisense compou will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-468963